查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1750632

全球镰状细胞性贫血快速 POC 检测市场规模、份额和趋势分析报告：按类型、技术、应用、机构类型、最终用途、分销渠道、地区和细分市场预测 2025-2030 年

Rapid Point-of-Care Testing for Sickle Cell Anemia Market Size, Share & Trends Analysis Report By Type, By Technology, By Age Group, By Distribution Channel, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 320 Pages | 商品交期: 2-10个工作天内

价格

镰状细胞性贫血快速 POC 检测市场成长与趋势：

根据 Grand View Research, Inc. 的新报告，全球镰状细胞性贫血快速 POC 检测市场规模预计到 2030 年将达到 5.2283 亿美元，2025 年至 2030 年期间的复合年增长率为 9.7%。

镰状细胞疾病 (SCD) 是一种遗传性血液疾病，会导致红血球形态异常，并可能因镰状细胞阻塞血流而引发剧烈疼痛、贫血和器官损伤。根据《血液学与相关科学期刊》(JHAS) 报导，印度是世界上镰状B珠蛋白等位基因频率最高的国家之一。早期准确检测SCD对于有效的管理和治疗至关重要。传统的诊断方法通常需要专业的医疗机构和设备齐全的实验室，而这些在资源匮乏的地区可能无法实现。鑑于这些挑战，快速即时检测 (POC) 已成为一种更有效率、更便捷的SCD诊断方法。

POC 检测具有许多优势，包括快速出结果、易于使用以及适用于分散式医疗环境。这些特点在 SCD 高发生地区尤其有利，因为早期诊断和早期疗育将显着改善患者的预后。透过及时检测，POC 检测可以降低未确诊 SCD 导致严重併发症和死亡的风险，有助于更好地管理疾病。此外，POC 检测在新生儿筛检计画中发挥重要作用，有助于在出生时识别受影响的婴儿并立即启动治疗。侧流免疫检测(LFIA) 的最新进展显着提高了 SCD 的诊断率，尤其是在资源匮乏的地区。其中一项创新进展是多重对偶基因特异性特异性重组聚合酵素(RPA) 检测。此外，将光学奈米粒子纳入 LFIA 平台提高了这些检测的敏感度和特异性，使其成为 SCD 和其他疾病的有力诊断工具。

另一项值得注意的创新是 E-junction 侧流免疫检测，专为在中低收入国家 (LMIC) 进行大规模 SCD筛检设计。这款价格低廉、易于使用的 POC 设备只需一滴全血即可诊断健康个体、SCD 患者和携带者。它的成本效益和可靠性使其成为传统诊断方法有限的地区的理想选择，有助于解决因延迟诊断而导致的高死亡率。同样，Sickle SCAN POC 设备在检测血红蛋白变体 HbA、HbS 和 HbC 方面表现出优异的灵敏度和特异性。该测试在液体和干血斑 (DBS) 中均有效，即使在胎儿血红蛋白 (HbF) 含量高的检体中也是如此，这使其成为资源受限地区广泛筛检的理想选择。 HemoTypeSC 测试是另一种有前景的早期 SCD 检测方法，它也具有高度的敏感度和特异性，使其特别适用于大规模筛检计画。通常由非政府组织主导的流动医疗团队和社区推广计画对于在资源匮乏的地区提供快速即时检测也至关重要。这些努力不仅改善了诊断服务的可近性，也提高了人们对SCD和早期疗育重要性的认识。此外，非政府组织与私人公司之间的伙伴关係也有助于津贴诊断检测，使其更便宜，并在各种医疗环境中推广。

诸如国家镰状细胞性贫血消除行动 (NSCAEM) 等有针对性的倡议旨在透过全民筛检、意识提升宣传活动和改善疾病管理，到 2047 年消除镰状性贫血这一公共卫生问题。该行动计划筛检约 7000 万名 0-40 岁人群，初期重点关注古吉拉突邦和马哈拉斯特拉邦等患病率较高的邦，同时与国家卫生使命 (NHM) 合作，以高效利用资源。

镰状细胞性贫血快速 POC 检测市场报告重点

  • 按类型划分，侧流免疫测量法凭藉其价格实惠、操作简便、结果快速准确等优势，在2024年占据51.66%的市场份额，占据市场领先地位。侧流免疫测定法能够检测多种血红蛋白变异体，适用于资源匮乏的环境，因此在全球诊断市场中日益普及。
  • 从技术面来看，血红素电泳技术凭藉其在血红蛋白病检测方面的高准确性，在2024年以48.99%的市占率领先市场。作为一种可靠的诊断方法，它能够准确识别镰状细胞疾病和其他血红蛋白变异体，这对于早期疗育和疾病管理至关重要。
  • 从应用角度来看，新生儿筛检（<12个月）预计将在2024年引领市场，并有望在预测期内实现最快的复合年增长率，这得益于人们对早期诊断的认识和重视程度的不断提高。透过POC检测进行早期发现，可以及时治疗，减少併发症，并改善患儿的长期预后。
  • 在国家措施和技术进步的推动下，政府实验室领域正在经历显着成长。印度医学研究理事会 (ICMR) 已核准现有的镰状细胞疾病筛检即时筛检(POC)，并鼓励各邦实施一级或二级筛检方法。
  • 镰状细胞病患疾病率不断上升和及时诊断需求的推动，医院和诊所终端用途领域正在经历显着增长。
  • 从分销管道来看，由于对便捷高效的诊断解决方案的需求不断增长，B2B 领域正在经历显着增长。各公司正在建立策略伙伴关係关係，以扩大产品供应并拓展更广阔的市场。
  • 在对可访问和高效的诊断解决方案的需求不断增长的推动下，镰状细胞性贫血快速 POC 检测行业由北美主导，2024 年的收入份额为 43.97%。这种扩张归因于慢性病盛行率上升、诊断技术的进步以及政府和私人机构资金增加等因素。
  • BioMedomics 和 Silver Lake Research 等主要企业凭藉 Sickle SCAN 和 HemoTypeSC 等高灵敏度和高特异性检测引领市场。随着这些公司提升诊断能力、缩短週转时间并协助镰状细胞疾病的早期疗育，市场有望成长。

目录

第一章调查方法与范围

第二章执行摘要

镰状细胞性贫血快速 POC 检测市场变数、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 镰状细胞性贫血快速 POC 检测市场分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

镰状细胞性贫血快速 POC 检测市场：类型估计和趋势分析

  • 2024 年及 2030 年各类型市场占有率
  • 细分仪表板
  • 全球镰状细胞性贫血快速 POC 检测市场：按类型展望
  • 市场规模、预测与趋势分析（2018-2030年）
    • 侧流免疫测量
    • 纸本快速诊断
    • 其他的

镰状细胞性贫血快速 POC 检测市场：技术评估与趋势分析

  • 2024 年及 2030 年技术市场占有率
  • 细分仪表板
  • 全球镰状细胞性贫血快速即时检测市场：技术展望
  • 市场规模、预测与趋势分析（2018-2030年）
    • 血红素电泳
    • 聚合酵素链锁反应（PCR）
    • 等温扩增试验
    • 其他的

第六章镰状细胞性贫血快速POC检测市场：应用评估与趋势分析

  • 2024 年及 2030 年各应用领域的市场占有率
  • 细分仪表板
  • 全球镰状细胞性贫血快速即时检测市场：应用前景
  • 市场规模、预测与趋势分析（2018-2030年）
    • 新生儿筛检（<12个月）
    • 成人筛检（25-60岁）
    • 其他年龄层（1-25岁及60岁以上）

镰状细胞性贫血快速 POC 检测市场：机构类型估计与趋势分析

  • 2024 年及 2030 年机构类型市场占有率
  • 细分仪表板
  • 全球镰状细胞性贫血快速 POC 检测市场：依机构类型展望
  • 市场规模、预测与趋势分析（2018-2030年）
    • 政府实验室
    • 私人实验室
    • 企业实验室
    • PPP（官民合作关係）

镰状细胞性贫血快速 POC 检测市场：最终用途估计与趋势分析

  • 2024 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 全球镰状细胞性贫血快速即时检测市场：最终用途展望
  • 市场规模、预测与趋势分析（2018-2030年）
    • 研究所
    • 医院和诊所
    • 诊断实验室
    • 居家照护环境
    • 其他的

镰状细胞性贫血快速 POC 检测市场：通路评估与趋势分析

  • 2024年及2030年分销通路市场占有率
  • 细分仪表板
  • 全球镰状细胞性贫血快速 POC 检测市场：通路展望
  • 市场规模、预测与趋势分析（2018-2030年）
    • B2B（企业对企业）
    • B2C（企业对消费者）

镰状细胞性贫血快速 POC 检测市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 市场规模、预测与趋势分析（2018-2030年）
  • 北美洲
    • 北美：SWOT分析
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲：SWOT分析
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区：SWOT分析
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲：SWOT分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十一章竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 主要客户
    • 主要企业市场占有率分析（2024年）
    • BIOMEDOMICS INC.
    • Silver Lake Research Corporation
    • Bio-Rad Laboratories, Inc.
    • Trivitron Healthcare
    • Hemex Health
    • Sysmex Corporation
    • EKF Diagnostics Holdings plc.
    • HemoCue America（Danaher）
    • Rapid Point-of-Care Testing for Sickle Cell Anemias Inc
Product Code: GVR-4-68040-567-0

Rapid Point-of-Care Testing for Sickle Cell Anemia Market Growth & Trends:

The global rapid point-of-care testing for sickle cell anemia market size is expected to reach USD 522.83 million by 2030, registering a CAGR of 9.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Sickle Cell Disease (SCD) is a genetic blood disorder that results in the production of abnormally shaped red blood cells, leading to severe pain, anemia, and potential organ damage due to these sickle-shaped cells obstructing blood flow. India, according to the Journal of Hematology and Allied Science (JHAS), has one of the highest frequencies of the sickle B-globin allele. Early and accurate detection of SCD is critical for effective management and treatment. Traditional diagnostic methods often require specialized healthcare facilities and well-equipped laboratories, which may be inaccessible in resource-limited areas. This challenge has driven the growth of rapid point-of-care (POC) testing technologies, offering a more efficient and accessible alternative for diagnosing SCD.

POC testing offers several benefits, including fast results, ease of use, and suitability for decentralized healthcare settings. These features are particularly advantageous in regions with high SCD prevalence, where early diagnosis and intervention can substantially improve patient outcomes. By enabling timely detection, POC testing helps in better disease management, reducing the risk of severe complications and mortality associated with undiagnosed SCD. Furthermore, POC tests play a key role in newborn screening programs, helping to identify affected infants at birth and begin treatment immediately. Recent advancements in lateral flow immunoassays (LFIA) have significantly improved the diagnosis of SCD, particularly in low-resource settings. One innovative development is the multiplexed, allele-specific recombinase polymerase amplification (RPA) assay, which uses a lateral flow readout to detect multiple mutations in the B-globin gene, the primary cause of SCD, offering an efficient and accurate rapid diagnostic method. Additionally, integrating optical nanoparticles into LFIA platforms has enhanced the sensitivity and specificity of these tests, making them powerful diagnostic tools for SCD and other diseases.

Another notable innovation is the E-junction lateral flow immunoassay, designed for large-scale SCD screening in low- and middle-income countries (LMICs). This affordable, user-friendly POC device can diagnose healthy individuals, SCD patients, and carriers using just a single drop of whole blood. Its cost-effectiveness and reliability make it ideal for areas with limited access to traditional diagnostic methods, helping address the high mortality rates caused by delayed diagnoses. Similarly, the Sickle SCAN POC device demonstrates impressive sensitivity and specificity in detecting hemoglobin variants HbA, HbS, and HbC. It works effectively with both liquid blood and dried blood spots (DBS), even in samples containing high levels of fetal hemoglobin (HbF), making it an excellent choice for widespread screening in resource-constrained regions. The HemoTypeSC test, another promising tool for early SCD detection, is also highly sensitive and specific, particularly useful for large-scale screening programs. Mobile health units and community outreach programs, often led by NGOs, are also integral to providing rapid POC testing in resource-poor settings. These efforts not only enhance access to diagnostic services but also raise awareness about SCD and the importance of early intervention. Moreover, partnerships between NGOs and private companies have helped subsidize diagnostic tests, making them more affordable and scalable across various healthcare environments.

Targeted initiatives, such as the National Sickle Cell Anaemia Elimination Mission (NSCAEM), aim to eradicate sickle cell anemia as a public health issue by 2047 through universal screening, awareness campaigns, and improved disease management. The mission aims to screen about 70 million people aged 0-40, initially focusing on high-prevalence states like Gujarat and Maharashtra, while collaborating with the National Health Mission (NHM) for effective resource utilization.

Rapid Point-of-Care Testing for Sickle Cell Anemia Market Report Highlights:

  • Based on type, the lateral flow immunoassay segment led the market in 2024 with a 51.66% share, due to its affordability, ease of use, and fast, accurate results. LFIA's ability to detect multiple hemoglobin variants and its suitability for low-resource settings contribute to its increasing adoption in global diagnostics.
  • Based on technology, the hemoglobin electrophoresis segment led the market in 2024 with a 48.99% share, driven by its high accuracy in detecting hemoglobinopathies. As a reliable diagnostic method, it allows for precise identification of sickle cell disease and other hemoglobin variants, making it crucial for early intervention and disease management.
  • Based on age group, the newborn screening (12 months and below) segment led the market in 2024 and is expected to witness the fastest CAGR during the forecast period, due to growing awareness and the importance of early diagnosis. Early detection through POC testing allows for prompt treatment, reducing complications and improving long-term outcomes for affected infants.
  • The government laboratories sector type segment is experiencing significant growth, driven by national initiatives and technological advancements. The Indian Council of Medical Research (ICMR) has endorsed existing POC tests for sickle cell disease screening, encouraging states to implement one or two-level screening approaches.
  • The hospitals & clinics end use segment is experiencing substantial growth, driven by the increasing prevalence of sickle cell disease and the demand for timely diagnostics.
  • Based on distribution channel, the Business-to-Business (B2B) segment is experiencing significant growth, driven by increasing demand for accessible and efficient diagnostic solutions. Companies are forming strategic partnerships to expand their product offerings and reach broader markets.
  • North America dominated the global Rapid point-of-care testing for sickle cell anemia industry with a revenue share of 43.97% in 2024, driven by increasing demand for accessible and efficient diagnostic solutions. This expansion is attributed to factors such as the rising prevalence of chronic diseases, advancements in diagnostic technologies, and increased funding from government and private institutions.
  • Companies like BioMedomics and Silver Lake Research are leading the way with highly sensitive and specific tests, such as Sickle SCAN and HemoTypeSC, respectively, while others are leveraging global distribution networks to reach underserved populations. The market is poised for growth as these players work to enhance diagnostic capabilities, reduce turnaround times, and support early intervention efforts for sickle cell disease

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Technology
    • 1.2.3. Age group
    • 1.2.4. Sector Type
    • 1.2.5. End Use
    • 1.2.6. Distribution Channel
    • 1.2.7. Regional scope
    • 1.2.8. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. Technology Outlook
    • 2.2.3. Age Group Outlook
    • 2.2.4. Sector Type
    • 2.2.5. End Use Outlook
    • 2.2.6. Distribution Channel
    • 2.2.7. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Rapid Point-of-Care Testing for Sickle Cell Anemia Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising demand for personalized medicine and genomic research
      • 3.2.1.2. Growing prevalence of sickle cell disease (SCD)
      • 3.2.1.3. Advancements in diagnostic technology
      • 3.2.1.4. Government and NGO initiatives for early point-of-care (POC) screening
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited accessibility to advanced technologies
  • 3.3. Rapid Point-of-Care Testing for Sickle Cell Anemia Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Lateral Flow Immunoassay
      • 4.4.1.1. Lateral Flow Immunoassay market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Paper-Based Rapid Diagnostics
      • 4.4.2.1. Paper-Based Rapid Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Others
      • 4.4.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hemoglobin Electrophoresis
      • 5.4.1.1. Hemoglobin Electrophoresis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Polymerase Chain Reaction (PCR)
      • 5.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Isothermal Amplification Assays
      • 5.4.3.1. Isothermal Amplification Assays market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Newborn Screening (12 months and below)
      • 6.4.1.1. Newborn Screening (12 months and below) market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Adult Screening (25 to 60 years)
      • 6.4.2.1. Adult Screening (25 to 60 years) market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Other Age Groups (1 to 25 & Above 60 years)
      • 6.4.3.1. Other Age Groups (1 to 25 & Above 60 years) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Sector Type Estimates & Trend Analysis

  • 7.1. Sector Type Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Sector Type Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Government Labs
      • 7.4.1.1. Government Labs market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Private Labs
      • 7.4.2.1. Private Labs market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Corporate Labs
      • 7.4.3.1. Corporate Labs market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. PPP (Public-Private-Partnerships)
      • 7.4.4.1. PPP (Public-Private-Partnerships) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: End Use Estimates & Trend Analysis

  • 8.1. End Use Market Share, 2024 & 2030
  • 8.2. Segment Dashboard
  • 8.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by End Use Outlook
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 8.4.1. Research Institutions
      • 8.4.1.1. Research Institutions market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Hospitals & Clinics
      • 8.4.2.1. Hospitals & Clinics market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. Diagnostic Laboratories
      • 8.4.3.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Homecare Settings
      • 8.4.4.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Others
      • 8.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Distribution Channel Estimates & Trend Analysis

  • 9.1. Distribution Channel Market Share, 2024 & 2030
  • 9.2. Segment Dashboard
  • 9.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Distribution Channel Outlook
  • 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 9.4.1. B2B (Business-to-Business)
      • 9.4.1.1. B2B (Business-to-Business) market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.2. B2C (Business-to-Consumer)
      • 9.4.2.1. B2C (Business-to-Consumer) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2024 & 2030
  • 10.2. Regional Market Dashboard
  • 10.3. Global Regional Market Snapshot
  • 10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.5. North America
    • 10.5.1. North America: SWOT Analysis
    • 10.5.2. U.S.
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Regulatory framework
      • 10.5.2.3. Competitive scenario
      • 10.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.3. Canada
      • 10.5.3.1. Key country dynamics
      • 10.5.3.2. Regulatory framework
      • 10.5.3.3. Competitive scenario
      • 10.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.4. Mexico
      • 10.5.4.1. Key country dynamics
      • 10.5.4.2. Regulatory framework
      • 10.5.4.3. Competitive scenario
      • 10.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6. Europe
    • 10.6.1. Europe: SWOT Analysis
    • 10.6.2. UK
      • 10.6.2.1. Key country dynamics
      • 10.6.2.2. Regulatory framework
      • 10.6.2.3. Competitive scenario
      • 10.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.3. Germany
      • 10.6.3.1. Key country dynamics
      • 10.6.3.2. Regulatory framework
      • 10.6.3.3. Competitive scenario
      • 10.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.4. France
      • 10.6.4.1. Key country dynamics
      • 10.6.4.2. Regulatory framework
      • 10.6.4.3. Competitive scenario
      • 10.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.5. Italy
      • 10.6.5.1. Key country dynamics
      • 10.6.5.2. Regulatory framework
      • 10.6.5.3. Competitive scenario
      • 10.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.6. Spain
      • 10.6.6.1. Key country dynamics
      • 10.6.6.2. Regulatory framework
      • 10.6.6.3. Competitive scenario
      • 10.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.7. Norway
      • 10.6.7.1. Key country dynamics
      • 10.6.7.2. Regulatory framework
      • 10.6.7.3. Competitive scenario
      • 10.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.8. Sweden
      • 10.6.8.1. Key country dynamics
      • 10.6.8.2. Regulatory framework
      • 10.6.8.3. Competitive scenario
      • 10.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.9. Denmark
      • 10.6.9.1. Key country dynamics
      • 10.6.9.2. Regulatory framework
      • 10.6.9.3. Competitive scenario
      • 10.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7. Asia Pacific
    • 10.7.1. Asia Pacific: SWOT Analysis
    • 10.7.2. Japan
      • 10.7.2.1. Key country dynamics
      • 10.7.2.2. Regulatory framework
      • 10.7.2.3. Competitive scenario
      • 10.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.3. China
      • 10.7.3.1. Key country dynamics
      • 10.7.3.2. Regulatory framework
      • 10.7.3.3. Competitive scenario
      • 10.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.4. India
      • 10.7.4.1. Key country dynamics
      • 10.7.4.2. Regulatory framework
      • 10.7.4.3. Competitive scenario
      • 10.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.5. Australia
      • 10.7.5.1. Key country dynamics
      • 10.7.5.2. Regulatory framework
      • 10.7.5.3. Competitive scenario
      • 10.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.6. South Korea
      • 10.7.6.1. Key country dynamics
      • 10.7.6.2. Regulatory framework
      • 10.7.6.3. Competitive scenario
      • 10.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.7. Thailand
      • 10.7.7.1. Key country dynamics
      • 10.7.7.2. Regulatory framework
      • 10.7.7.3. Competitive scenario
      • 10.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.8. Latin America
    • 10.8.1. Latin America: SWOT Analysis
    • 10.8.2. Brazil
      • 10.8.2.1. Key country dynamics
      • 10.8.2.2. Regulatory framework
      • 10.8.2.3. Competitive scenario
      • 10.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.8.3. Argentina
      • 10.8.3.1. Key country dynamics
      • 10.8.3.2. Regulatory framework
      • 10.8.3.3. Competitive scenario
      • 10.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.9. MEA
    • 10.9.1. MEA: SWOT Analysis
    • 10.9.2. South Africa
      • 10.9.2.1. Key country dynamics
      • 10.9.2.2. Regulatory framework
      • 10.9.2.3. Competitive scenario
      • 10.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.3. Saudi Arabia
      • 10.9.3.1. Key country dynamics
      • 10.9.3.2. Regulatory framework
      • 10.9.3.3. Competitive scenario
      • 10.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.4. UAE
      • 10.9.4.1. Key country dynamics
      • 10.9.4.2. Regulatory framework
      • 10.9.4.3. Competitive scenario
      • 10.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.5. Kuwait
      • 10.9.5.1. Key country dynamics
      • 10.9.5.2. Regulatory framework
      • 10.9.5.3. Competitive scenario
      • 10.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 11.2. Company/Competition Categorization
  • 11.3. Vendor Landscape
    • 11.3.1. List of key distributors and channel partners
    • 11.3.2. Key customers
    • 11.3.3. Key company market share analysis, 2024
    • 11.3.4. BIOMEDOMICS INC.
      • 11.3.4.1. Company overview
      • 11.3.4.2. Financial performance
      • 11.3.4.3. Services benchmarking
      • 11.3.4.4. Strategic initiatives
    • 11.3.5. Silver Lake Research Corporation
      • 11.3.5.1. Company overview
      • 11.3.5.2. Financial performance
      • 11.3.5.3. Services benchmarking
      • 11.3.5.4. Strategic initiatives
    • 11.3.6. Bio-Rad Laboratories, Inc.
      • 11.3.6.1. Company overview
      • 11.3.6.2. Financial performance
      • 11.3.6.3. Services benchmarking
      • 11.3.6.4. Strategic initiatives
    • 11.3.7. Trivitron Healthcare
      • 11.3.7.1. Company overview
      • 11.3.7.2. Financial performance
      • 11.3.7.3. Services benchmarking
      • 11.3.7.4. Strategic initiatives
    • 11.3.8. Hemex Health
      • 11.3.8.1. Company overview
      • 11.3.8.2. Financial performance
      • 11.3.8.3. Services benchmarking
      • 11.3.8.4. Strategic initiatives
    • 11.3.9. Sysmex Corporation
      • 11.3.9.1. Company overview
      • 11.3.9.2. Financial performance
      • 11.3.9.3. Services benchmarking
      • 11.3.9.4. Strategic initiatives
    • 11.3.10. EKF Diagnostics Holdings plc.
      • 11.3.10.1. Company overview
      • 11.3.10.2. Financial performance
      • 11.3.10.3. Services benchmarking
      • 11.3.10.4. Strategic initiatives
    • 11.3.11. HemoCue America (Danaher)
      • 11.3.11.1. Company overview
      • 11.3.11.2. Financial performance
      • 11.3.11.3. Services benchmarking
      • 11.3.11.4. Strategic initiatives
    • 11.3.12. Rapid Point-of-Care Testing for Sickle Cell Anemias Inc
      • 11.3.12.1. Company overview
      • 11.3.12.2. Financial performance
      • 11.3.12.3. Services benchmarking
      • 11.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 List of Secondary Sources
  • Table 3 Regulatory Framework
  • Table 4 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 6 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 7 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 USD Million
  • Table 8 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 9 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 10 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 12 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 14 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 15 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 16 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 17 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 19 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 20 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 21 U.S Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 22 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 23 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 25 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 26 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 27 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 28 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 29 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 31 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 32 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 33 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 34 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 35 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 37 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 39 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 40 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 41 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 42 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 44 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 45 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 46 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 47 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 48 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 51 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 52 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 53 Germany America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 54 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 56 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 57 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 58 France Rapid Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 59 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 60 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 62 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 63 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 64 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 65 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 66 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 68 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 69 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 70 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 71 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 72 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 76 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 77 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 78 Asia-Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 79 Asia-Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 81 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 82 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 83 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 84 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 85 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 87 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 88 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 89 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 90 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 91 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 93 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 94 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 95 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 96 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 97 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 98 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 99 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 100 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 101 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 102 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 103 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 104 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 105 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 106 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 107 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 108 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 109 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 111 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 112 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 113 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 114 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 115 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 116 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 117 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 118 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 119 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 120 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 121 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 122 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 123 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 124 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 125 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 126 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 127 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 128 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 129 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 130 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 131 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 132 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 133 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 134 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 135 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 136 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 137 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 138 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 139 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 140 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 141 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 142 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 143 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 144 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 145 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 146 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 147 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million) million
  • Table 148 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 149 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 150 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 151 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 152 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 153 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Rapid Point-of-Care Testing for Sickle Cell Anemia: market outlook
  • Fig. 14 Rapid Point-of-Care Testing for Sickle Cell Anemia competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook.
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Rapid Point-of-Care Testing for Sickle Cell Anemia driver impact
  • Fig. 20 Rapid Point-of-Care Testing for Sickle Cell Anemia restraint impact
  • Fig. 21 Rapid Point-of-Care Testing for Sickle Cell Anemia strategic initiatives analysis
  • Fig. 22 Rapid Point-of-Care Testing for Sickle Cell Anemia: Type movement analysis
  • Fig. 23 Rapid Point-of-Care Testing for Sickle Cell Anemia: Type outlook and key takeaways
  • Fig. 24 Lateral Flow Immunoassay market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Paper-Based Rapid Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Rapid Point-of-Care Testing for Sickle Cell Anemia: Technology movement analysis
  • Fig. 28 Rapid Point-of-Care Testing for Sickle Cell Anemia: Technology outlook and key takeaways
  • Fig. 29 Hemoglobin Electrophoresis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Isothermal Amplification Assays market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Rapid Point-of-Care Testing for Sickle Cell Anemia: Age Group movement analysis
  • Fig. 34 Rapid Point-of-Care Testing for Sickle Cell Anemia: Age Group outlook and key takeaways
  • Fig. 35 Newborn Screening (12 months and below) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Adult Screening (25 to 60 years) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Other Age Groups (1 to 25 & Above 60 years) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Rapid Point-of-Care Testing for Sickle Cell Anemia: Sector Type movement analysis
  • Fig. 39 Rapid Point-of-Care Testing for Sickle Cell Anemia: Sector Type outlook and key takeaways
  • Fig. 40 Government Labs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Private Labs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Corporate Labs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 PPP (Public-Private-Partnerships) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Rapid Point-of-Care Testing for Sickle Cell Anemia: End use movement analysis
  • Fig. 45 Rapid Point-of-Care Testing for Sickle Cell Anemia: End use outlook and key takeaways
  • Fig. 46 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Diagnostics Laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Research Institutions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Homecare Settings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Rapid Point-of-Care Testing for Sickle Cell Anemia: Distribution movement analysis
  • Fig. 52 Rapid Point-of-Care Testing for Sickle Cell Anemia: Distribution Channel outlook and key takeaways
  • Fig. 53 B2B (Business-to-Business) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 B2C (Business-to-Consumer) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Global rapid point-of-care testing for sickle cell anemia market: Regional movement analysis
  • Fig. 56 Global rapid point-of-care testing for sickle cell anemia market: Regional outlook and key takeaways
  • Fig. 57 Global rapid point-of-care testing for sickle cell anemia market shares and leading players
  • Fig. 58 North America
  • Fig. 59 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 U.S.
  • Fig. 61 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Canada
  • Fig. 63 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Mexico
  • Fig. 65 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Europe
  • Fig. 67 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 UK
  • Fig. 69 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Germany
  • Fig. 71 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 France
  • Fig. 73 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Italy
  • Fig. 75 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Spain
  • Fig. 77 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Denmark
  • Fig. 79 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Sweden
  • Fig. 81 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Norway
  • Fig. 83 Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Asia Pacific
  • Fig. 85 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 China
  • Fig. 87 China market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Japan
  • Fig. 89 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 India
  • Fig. 91 India market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Thailand
  • Fig. 93 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 South Korea
  • Fig. 95 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 96 Australia
  • Fig. 97 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Latin America
  • Fig. 99 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Brazil
  • Fig. 101 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 102 Argentina
  • Fig. 103 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 104 Middle East and Africa
  • Fig. 105 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 106 South Africa
  • Fig. 107 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 108 Saudi Arabia
  • Fig. 109 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 110 UAE
  • Fig. 111 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 112 Kuwait
  • Fig. 113 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 114 Market share of key market players- Rapid Point-of-Care Testing for Sickle Cell Anemia